Celltrion Juggles Biosimilar Market Share As It Shifts To Direct Marketing

Korean Firm Also Settles Avastin Litigation To Allow CT-P16 Bevacizumab Launch

 
• By Chloe Kent

Celltrion Healthcare was ultimately able to increase its revenue by 16.7%, with stronger growth expected in H2.

Man juggling
Market share fluctuated across Celltrion's biosimilar products. • Source: Shutterstock

More from Earnings

More from Business